CRSP
Price
$51.11
Change
-$1.08 (-2.07%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
4.97B
96 days until earnings call
Intraday BUY SELL Signals
PRME
Price
$3.33
Change
-$0.22 (-6.20%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
639.01M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRSP vs PRME

Header iconCRSP vs PRME Comparison
Open Charts CRSP vs PRMEBanner chart's image
CRISPR Therapeutics AG
Price$51.11
Change-$1.08 (-2.07%)
Volume$123.74K
Capitalization4.97B
Prime Medicine
Price$3.33
Change-$0.22 (-6.20%)
Volume$130.51K
Capitalization639.01M
CRSP vs PRME Comparison Chart in %
View a ticker or compare two or three
VS
CRSP vs. PRME commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and PRME is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (CRSP: $52.19 vs. PRME: $3.55)
Brand notoriety: CRSP and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 108% vs. PRME: 105%
Market capitalization -- CRSP: $4.97B vs. PRME: $639.01M
CRSP [@Biotechnology] is valued at $4.97B. PRME’s [@Biotechnology] market capitalization is $639.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 6 bearish.
  • PRME’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both CRSP and PRME are a bad buy in the short-term.

Price Growth

CRSP (@Biotechnology) experienced а -8.42% price change this week, while PRME (@Biotechnology) price change was -19.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 17, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.97B) has a higher market cap than PRME($639M). CRSP YTD gains are higher at: 32.597 vs. PRME (21.575). PRME has higher annual earnings (EBITDA): -197.38M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. PRME (102M). PRME has less debt than CRSP: PRME (120M) vs CRSP (215M). CRSP has higher revenues than PRME: CRSP (35M) vs PRME (4.96M).
CRSPPRMECRSP / PRME
Capitalization4.97B639M778%
EBITDA-533.5M-197.38M270%
Gain YTD32.59721.575151%
P/E RatioN/AN/A-
Revenue35M4.96M706%
Total Cash1.72B102M1,687%
Total Debt215M120M179%
FUNDAMENTALS RATINGS
CRSP vs PRME: Fundamental Ratings
CRSP
PRME
OUTLOOK RATING
1..100
5859
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9599
PRICE GROWTH RATING
1..100
6040
P/E GROWTH RATING
1..100
71100
SEASONALITY SCORE
1..100
5041

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (42) in the null industry is in the same range as CRSP (71) in the Biotechnology industry. This means that PRME’s stock grew similarly to CRSP’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as CRSP (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (95) in the Biotechnology industry is in the same range as PRME (99) in the null industry. This means that CRSP’s stock grew similarly to PRME’s over the last 12 months.

PRME's Price Growth Rating (40) in the null industry is in the same range as CRSP (60) in the Biotechnology industry. This means that PRME’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (71) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that CRSP’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPPRME
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 21 days ago
80%
Bullish Trend about 1 month ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signal:
Gain/Loss:
PRME
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NFFFX98.430.44
+0.45%
American Funds New World F2
LMUSX28.410.07
+0.25%
Franklin U.S. Large Cap Equity FI
SCJAX8.210.01
+0.12%
Steward Covered Call Income A
CHTVX24.900.02
+0.08%
Invesco Charter R5
MSMFX15.87N/A
N/A
Morgan Stanley Inst Discovery C

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
-5.47%
BEAM - CRSP
70%
Closely correlated
-2.71%
RXRX - CRSP
68%
Closely correlated
-1.27%
PRME - CRSP
61%
Loosely correlated
-9.44%
CRBU - CRSP
61%
Loosely correlated
+0.89%
NTLA - CRSP
59%
Loosely correlated
-6.78%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-9.44%
CRSP - PRME
60%
Loosely correlated
-5.47%
BEAM - PRME
60%
Loosely correlated
-2.71%
RXRX - PRME
55%
Loosely correlated
-1.27%
EDIT - PRME
51%
Loosely correlated
+1.50%
ABCL - PRME
48%
Loosely correlated
-1.00%
More